Liposomal irinotecan and 5‑FU with a PD‑L1 blocker plus an anti‑angiogenic pill, with or without focused radiation, for second‑line metastatic pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single‑arm, prospective Phase 2 study planning to enroll about 56 patients with metastatic pancreatic cancer who progressed after first‑line therapy. All participants receive liposomal irinotecan (nal‑IRI) plus 5‑fluorouracil/leucovorin together with a PD‑L1 antibody (bemosubaemab) and the multi‑targeted anti‑angiogenic agent anlotinib; a second cohort also receives stereotactic body radiation therapy (SBRT). Treatment is given in repeated 3‑week cycles with irinotecan and 5‑FU on days 1 and 15, anlotinib orally on days 1–14, and PD‑L1 antibody every 3 weeks, and patients are followed for response, safety, and survival. Enrollment requires meeting prespecified laboratory and performance status criteria and signing informed consent.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years and ≤ 75 years, ECOG score of ≤2 points, expected survival time ≥ 3 months.
2. Patients with histologically or cytologically confirmed advanced metastatic pancreatic cancer.
3. Imaging suggests distant measurable lesions.
4. Failure of first-line therapy and no use of fluorouracil, irinotecan, or liposomal irinotecan drugs in the first-line therapy.

Patients need to meet the following hematologic indicators e1. Neutrophil count ≥ 1.5×109/L e2. Hemoglobin ≥ 10 g/dL e3. Platelet count ≥ 100×109/L f. Patients need to meet the following biochemical parameters f1. Total bilirubin ≤ 1.5× upper limit of normal (ULN) f2. AST and ALT \<1.5×ULN f3. Creatinine clearance ≥ 60ml/min g. Patients of childbearing age need to take appropriate protective measures (contraception or other methods of birth control) before enrollment and during the trial.

H. Has signed an informed consent form. i. Able to follow the study protocol and follow-up process.

Exclusion Criteria:

1. Have received second-line or more anti-tumor therapy in the past.
2. First-line treatment with fluorouracil, irinotecan or liposomal irinotecan, etc.
3. Patient has a prior history of other tumors, unless it is cervical cancer in situ, treated squamous cell carcinoma or bladder epithelial tumors (Ta and TIS) or other malignancies that have received curative therapy (at least more than 5 years prior to enrollment).
4. Patient has an active bacterial or fungal infection (≥ 3rd edition NCI-CTC2 grade).

Patient has HIV, HCV, HBV infection, uncontrolled coronary artery disease or asthma, uncontrolled cerebrovascular disease or other disease deemed non-enrollable by the investigator.

f. Patients with autoimmune diseases or immunodeficiencies who should be treated with immunosuppressive drugs.

g. Pregnant and lactating women. Women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment.

h. Substance abuse, clinical or psychological, or social factors that compromise informed consent or study conduct.

i. Those who may be allergic to treatment drugs.

Where it's running

• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Juan Du, M.D. Ph.D
• Email: dujunglyy@163.com
• Phone: +86-025-83106666

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NALIRIFOX plus adebrelimab and PULSAR as first-line treatment for advanced pancreatic cancer

  This study tests a combination of NALIRIFOX chemotherapy with adebrelimab and PULSAR as first-line therapy for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma to see if it is safe and shows initial signs of effectiveness.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07595172

• HRS-4642 plus AG vs AG alone in first-line advanced pancreatic cancer with KRAS G12D mutation

  This trial tests whether adding HRS-4642 to AG therapy helps people with KRAS G12D‑mutant advanced or metastatic pancreatic cancer in their first-line treatment.

  Recruiting Phase 3 Jiangsu HengRui Medicine Co., Ltd. · Shanghai, Shanghai Municipality · NCT07232875

• HRS-4642 with chemotherapy and immunotherapy for advanced pancreatic cancer

  This study tries adding HRS-4642 to standard chemotherapy and/or an immune therapy to see if it helps people with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma.

  Recruiting Phase 1/2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07296341

• Evaluating BEY1107 with Gemcitabine for Pancreatic Cancer

  This study is testing a new drug called BEY1107, alone and with another medication called gemcitabine, to see if it can help people with advanced pancreatic cancer feel better and improve their treatment options.

  Recruiting Phase 1/2 BeyondBio Inc. · Seoul · NCT03579836

• CP-383 for advanced or metastatic solid tumors

  This trial tests whether the oral drug CP-383 can slow or stop growth in adults with advanced or metastatic solid tumors who have exhausted standard treatments.

  Recruiting at 13 sites Phase 1/2 Tasca Therapeutics · Denver, Colorado and 12 other locations · NCT07030257

• INV-8989 in KRAS G12D-mutant advanced solid tumors

  This study tests INV-8989 to see if it can be safely given and potentially help patients with KRAS G12D-mutant advanced solid tumors.

  Recruiting Phase 1/2 Shenzhen Ionova Life Sciences Co., Ltd. · Guangzhou, Guangdong · NCT07610798

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.